The authors of this retrospective study had the goal of evaluating the effectiveness of radiomics signatures in order to predict the tumor response of non-small cell lung cancer (NSCLC) patients who were treated with first-line chemotherapy, targeted therapy, or a combination of the two. The authors determined that radiomics signatures based on pre-treatment CT scans can accurately predict tumor response in NSCLC patients after first-line chemotherapy and/or targeted therapy treatments and have a promising future as prognostic imaging biomarkers.
Key points
- The radiomics signature extracted from baseline CT images in patients with NSCLC can predict response to first-line chemotherapy, targeted therapy, or both treatments with an AUC = 0.746 (95% CI, 0.646–0.846).
- The radiomics signature could be used as a new biomarker for quantitative analysis in radiology, which might provide value in decision-making and to define personalized treatments for cancer patients.
Authors: Fengchang Yang, Jiayi Zhang, Liu Zhou, Wei Xia, Rui Zhang, Haifeng Wei, Jinxue Feng, Xingyu Zhao, Junming Jian, Xin Gao & Shuanghu Yuan
